{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:11:27Z","timestamp":1754161887721,"version":"3.41.2"},"reference-count":81,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443296383"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.irn.2024.07.001","type":"book-chapter","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T18:54:12Z","timestamp":1729277652000},"page":"1-22","source":"Crossref","is-referenced-by-count":0,"title":["Introduction: Approved treatments for alcohol use disorder by regulatory agencies"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.irn.2024.07.001_bib1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1530-0277.1998.tb03872.x","article-title":"Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex","volume":"22","author":"Al Qatari","year":"1998","journal-title":"Alcohol, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.07.001_bib2","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/bs.irn.2024.07.001_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","article-title":"An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study","volume":"65","author":"Anton","year":"2008","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/bs.irn.2024.07.001_bib4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pbb.2012.08.019","article-title":"Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol","volume":"103","author":"Ashenhurst","year":"2012","journal-title":"Pharmacology Biochemistry & Behavior"},{"key":"10.1016\/bs.irn.2024.07.001_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/gbb.12785","article-title":"Sex differences in GABAA receptor subunit transcript expression are mediated by genotype in subjects with alcohol-related cirrhosis of the liver.","volume":"21","author":"Ashton","year":"2022","journal-title":"Genes, Brain, and Behavior"},{"key":"10.1016\/bs.irn.2024.07.001_bib6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/ADM.0000000000000992","article-title":"Pharmacotherapies for adults with alcohol use disorders: A systematic review and network meta-analysis","volume":"16","author":"Bahji","year":"2022","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/bs.irn.2024.07.001_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.biopsych.2009.07.026","article-title":"Suppression of alcohol preference by naltrexone in the rhesus macaque: A critical role of genetic variation at the \u03bc-opioid receptor gene locus","volume":"67","author":"Barr","year":"2010","journal-title":"Biological Psychiatry"},{"key":"10.1016\/bs.irn.2024.07.001_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archpsyc.64.3.369","article-title":"Association of a functional polymorphism in the \u03bc-opioid receptor gene with alcohol response and consumption in male rhesus macaques","volume":"64","author":"Barr","year":"2007","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/bs.irn.2024.07.001_bib9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.npp.1300598","article-title":"Increased attributable risk related to a functional \u03bc-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden","volume":"30","author":"Bart","year":"2005","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.001_bib10","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/sj.mp.4000331","article-title":"opioid receptor gene variants: Lack of association with alcohol dependence","volume":"2","author":"Bergen","year":"1997","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/bs.irn.2024.07.001_bib11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1471-4159.2004.02340.x","article-title":"Effect of the A118G polymorphism on binding affinity and agonist-mediated endocytosis, desensitization, and resensitization of the human \u03bc-opioid receptor","volume":"89","author":"Beyer","year":"2004","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/bs.irn.2024.07.001_bib12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0091-3057(84)80020-9","article-title":"A homotaurine derivative reduces the voluntary intake of ethanol by rats: Are cerebral GABA receptors involved?","volume":"21","author":"Boismare","year":"1984","journal-title":"Pharmacology Biochemistry & Behavior"},{"key":"10.1016\/bs.irn.2024.07.001_bib13","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1073\/pnas.95.16.9608","article-title":"Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: Possible implications for opiate addiction","volume":"95","author":"Bond","year":"1998","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/bs.irn.2024.07.001_bib14","first-page":"345","article-title":"Alcohol dependence and genes encoding \u03b12 and \u03b31 GABAA receptor subunits: Insights from humans and mice","volume":"34","author":"Borghese","year":"2012","journal-title":"Alcohol Research"},{"key":"10.1016\/bs.irn.2024.07.001_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev.clinpsy.3.022806.091455","article-title":"Relapse and relapse prevention","volume":"3","author":"Brandon","year":"2007","journal-title":"Annual Review of Clinical Psychology"},{"key":"10.1016\/bs.irn.2024.07.001_bib16","first-page":"311","article-title":"Physicochemical, pharmacological and pharmacokinetic study of a new GABAergic compound, calcium acetylhomotaurinate","volume":"10","author":"Chabenat","year":"1988","journal-title":"Methods & Findings in Experimental & Clinical Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.001_bib17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1369-1600.2012.00442.x","article-title":"Association of \u00b5-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: A systematic review and meta-analysis","volume":"17","author":"Chamorro","year":"2012","journal-title":"Addiction Biology"},{"key":"10.1016\/bs.irn.2024.07.001_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/alcalc\/35.2.176","article-title":"United Kingdom Multicentre Acamprosate Study (UKMAS): A 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol","volume":"35","author":"Chick","year":"2000","journal-title":"Alcohol and Alcoholism (Oxford, Oxfordshire)"},{"key":"10.1016\/bs.irn.2024.07.001_bib19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fpsyt.2018.00475","article-title":"Suppressing effect of baclofen on multiple alcohol-related behaviors in laboratory animals","volume":"9","author":"Colombo","year":"2018","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/bs.irn.2024.07.001_bib20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1126\/science.167.3920.1005","article-title":"Alcohol, amines, and alkaloids: A possible basis for alcohol addiction","volume":"167","author":"Davis","year":"1970","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.irn.2024.07.001_bib21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0091-3057(90)90019-E","article-title":"Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors","volume":"37","author":"DeHaven-Hudkins","year":"1990","journal-title":"Pharmacololgy, Biochemistry and Behavior"},{"key":"10.1016\/bs.irn.2024.07.001_bib22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1530-0277.2006.00052.x","article-title":"Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone","volume":"30","author":"Dunbar","year":"2006","journal-title":"Alcohol and Clinical Experimental Research"},{"key":"10.1016\/bs.irn.2024.07.001_bib23","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1111\/acer.13904","article-title":"Alcohol dehydrogenases, aldehyde dehydrogenases, and alcohol use disorders: A critical review","volume":"42","author":"Edenberg","year":"2018","journal-title":"Alcohol, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.07.001_bib24","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0022-3565(25)24051-4","article-title":"Binding affinity and selectivity of opioids at mu, delta, and kappa receptors in monkey brain membranes","volume":"271","author":"Emmerson","year":"1994","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.irn.2024.07.001_bib25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3389\/fphar.2019.00471","article-title":"Drinking levels and profiles of alcohol-addicted rats predict response to nalmefene","volume":"10","author":"Foo","year":"2019","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.001_bib26","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.281.14.1318","article-title":"Pharmacological treatment of alcohol dependence: A review of the evidence","volume":"281","author":"Garbutt","year":"1999","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/bs.irn.2024.07.001_bib27","unstructured":"GDS.\u00a0(2018). Global status report on alcohol and health 2018. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"10.1016\/bs.irn.2024.07.001_bib28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1530-0277.2007.00339.x","article-title":"Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: Results from the VA Cooperative Study","volume":"31","author":"Gelernter","year":"2007","journal-title":"Alcohol, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.07.001_bib29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/archpsyc.1996.01830030072011","article-title":"Enhanced sensitivity of pituitary \u03b2-endorphin to ethanol in subjects at high risk of alcoholism","volume":"53","author":"Gianoulakis","year":"1996","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/bs.irn.2024.07.001_bib30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002130050169","article-title":"Endogenous opioid systems and alcohol addiction","volume":"129","author":"Herz","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.irn.2024.07.001_bib31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1600-0773.1949.tb03393.x","article-title":"Site of the formation of acetaldehyde after ingestion of antabuse (tetraethylthiuramdisulphide) and alcohol","volume":"5","author":"Jacobsen","year":"1949","journal-title":"Acta Pharmacologica et Toxicologica (Copenh)"},{"key":"10.1016\/bs.irn.2024.07.001_bib32","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: A neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/bs.irn.2024.07.001_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.70359\/bhc2008v033p082","article-title":"From disulfiram to antabuse: The invention of a drug","volume":"33","author":"Kragh","year":"2008","journal-title":"Bulletin for the History of Chemistry"},{"key":"10.1016\/bs.irn.2024.07.001_bib34","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0893-133X(99)00135-9","article-title":"Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial","volume":"22","author":"Kranzler","year":"2000","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.001_bib35","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/antibiotics12030524","article-title":"Disulfiram: Mechanisms, applications, and challenges","volume":"12","author":"Lanz","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"8436","key":"10.1016\/bs.irn.2024.07.001_bib36","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0140-6736(85)91615-0","article-title":"Ability of calcium bis acetyl homotaurinate, a GABA agonist, to prevent relapse in weaned alcoholics","volume":"1","author":"Lhuintre","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/bs.irn.2024.07.001_bib37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/oxfordjournals.alcalc.a045057","article-title":"Acamprosate appears to decrease alcohol intake in weaned alcoholics","volume":"25","author":"Lhuintre","year":"1990","journal-title":"Alcohol and Alcoholism (Oxford, Oxfordshire)"},{"key":"10.1016\/bs.irn.2024.07.001_bib38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00228-010-0793-6","article-title":"The pharmacological treatment of opioid addiction\u2014A clinical perspective","volume":"66","author":"Lobmaier","year":"2010","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.001_bib39","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1126\/science.2467382","article-title":"Ethanol inhibits NMDA-activated ion current in hippocampal neurons","volume":"243","author":"Lovinger","year":"1989","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.irn.2024.07.001_bib40","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.euroneuro.2016.10.008","article-title":"Nalmefene for the management of alcohol dependence: Review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy","volume":"26","author":"Mann","year":"2016","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.001_bib41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/pcn.12914","article-title":"Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial","volume":"73","author":"Miyata","year":"2019","journal-title":"Psychiatry and Clinical Neurosciences"},{"key":"10.1016\/bs.irn.2024.07.001_bib42","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1530-0277.1998.tb03871.x","article-title":"Mechanism of action of acamprosate. Part I\u00a0Characterization\u00a0of\u00a0spermidine-sensitive\u00a0acamprosate\u00a0binding\u00a0site\u00a0in\u00a0rat\u00a0brain","volume":"22","author":"Naassila","year":"1998","journal-title":"Alcohol and Clinical Experimental Research"},{"key":"10.1016\/bs.irn.2024.07.001_bib43","unstructured":"National Collaborating Centre for Mental Health (NCCMH) Alcohol-use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence. (2011). Leicester and London: The British Psychological Society and the Royal College of Psychiatrists."},{"key":"10.1016\/bs.irn.2024.07.001_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2020.04.003","article-title":"Predicting relapse after alcohol use disorder treatment in a high-risk cohort: The roles of anhedonia and smoking","volume":"126","author":"Nguyen","year":"2020","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/bs.irn.2024.07.001_bib45","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence: A controlled study.","volume":"49","author":"O\u2019Malley","year":"1992","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/bs.irn.2024.07.001_bib46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13041-017-0325-8","article-title":"Role of GABAA receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model","volume":"10","author":"Olsen","year":"2017","journal-title":"Molecular Brain"},{"key":"10.1016\/bs.irn.2024.07.001_bib47","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.3390\/molecules26113296","article-title":"New disulfiram derivatives as MAGL-selective inhibitors","volume":"26","author":"Omran","year":"2021","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/bs.irn.2024.07.001_bib48","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s002130000666","article-title":"Adverse effects of oral naltrexone: Analysis of data from two clinical trials","volume":"154","author":"Oncken","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.irn.2024.07.001_bib49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/0971-8990.164826","article-title":"Tracing the journey of disulfiram. From an unintended discovery to a treatment option for alcoholism","volume":"20","author":"Pal","year":"2015","journal-title":"Journal of. Mental Health Human Behaviour"},{"key":"10.1016\/bs.irn.2024.07.001_bib50","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1530-0277.2002.tb02452.x","article-title":"The European NEAT program: An integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction","volume":"26","author":"Pelc","year":"2002","journal-title":"Alcohol, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.07.001_bib51","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.euroneuro.2018.03.017","article-title":"Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis","volume":"28","author":"Pierce","year":"2018","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.001_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.alcohol.2020.04.002","article-title":"On the interaction between BDNF and serotonin systems: The effects of long-term ethanol consumption in mice","volume":"87","author":"Popova","year":"2020","journal-title":"Alcohol (Fayetteville, N. Y.)"},{"key":"10.1016\/bs.irn.2024.07.001_bib53","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1097\/01.ALC.0000148114.34000.B9","article-title":"A polymorphism of the mu opioid receptor gene and sensitivity to the effects of alcohol in humans","volume":"28","author":"Ray","year":"2004","journal-title":"Alcohol, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.07.001_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuropharm.2017.01.017","article-title":"Genetic studies of alcohol dependence in the context of the addiction cycle","volume":"122","author":"Reilly","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2024.07.001_bib55","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/add.14191","article-title":"Baclofen: Its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis","volume":"113","author":"Rose","year":"2018","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/bs.irn.2024.07.001_bib56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/adb.12574","article-title":"Genome-wide association study of alcohol use disorder identification test (AUDIT) scores in 20 328 research participants of European ancestry","volume":"24","author":"Sanchez-Roige","year":"2019","journal-title":"Addiction Biology"},{"key":"10.1016\/bs.irn.2024.07.001_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119474","article-title":"Bioresponsive nanostructured systems for sustained naltrexone release and treatment of alcohol use disorder: Development and biological evaluation","volume":"585","author":"Santos","year":"2020","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/bs.irn.2024.07.001_bib58","first-page":"1097","article-title":"Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Archives of General Psychiatry, 53, 673-680","volume":"53","author":"Sass","year":"1996","journal-title":"Erratum in: (1996) Archives of General Psychiatry"},{"key":"10.1016\/bs.irn.2024.07.001_bib59","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1159\/000512763","article-title":"Calcium carbonate attenuates withdrawal and reduces craving: A randomized controlled trial in alcohol-dependent patients","volume":"27","author":"Schuster","year":"2021","journal-title":"European Addiction Research"},{"key":"10.1016\/bs.irn.2024.07.001_bib60","unstructured":"Sheedy, C. K., & Whitter, M. (2009). Guiding principles and elements of recovery-oriented systems of care: What do we know from the research? HHS Publication No. (SMA) 09\u20134439. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration."},{"key":"10.1016\/bs.irn.2024.07.001_bib61","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1152\/physrev.00013.2008","article-title":"Alcoholism: A systems approach from molecular physiology to addictive behavior","volume":"89","author":"Spanagel","year":"2009","journal-title":"Physiological Reviews"},{"key":"10.1016\/bs.irn.2024.07.001_bib62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0014-2999(96)00174-4","article-title":"Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat","volume":"305","author":"Spanagel","year":"1996","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.001_bib63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0014-2999(96)00175-6","article-title":"Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat","volume":"305","author":"Spanagel","year":"1996","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.001_bib64","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/npp.2013.264","article-title":"Acamprosate produces its anti-relapse effects via calcium","volume":"39","author":"Spanagel","year":"2014","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.001_bib65","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0014-2999(96)00176-8","article-title":"Acamprosate and alcohol: III. Effects on alcohol discrimination in the rat","volume":"305","author":"Spanagel","year":"1996","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.001_bib66","first-page":"13","article-title":"Naltrexone: A history and future directions","author":"Srivastava","year":"2018","journal-title":"Cerebrum, 2018, vcer-"},{"key":"10.1016\/bs.irn.2024.07.001_bib67","series-title":"StatPearls [Internet]","article-title":"Disulfiram","author":"Stokes","year":"2024"},{"key":"10.1016\/bs.irn.2024.07.001_bib68","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJM199905133401907","article-title":"Drug therapy for alcohol dependence","volume":"340","author":"Swift","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2024.07.001_bib69","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0022-3565(25)21011-4","article-title":"Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays","volume":"246","author":"Takemori","year":"1988","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.irn.2024.07.001_bib70","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev.pa.32.040192.001323","article-title":"Selective naltrexone-derived opioid receptor antagonists","volume":"32","author":"Takemori","year":"1992","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/bs.irn.2024.07.001_bib71","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tips.2014.04.009","article-title":"Alcohol dependence: molecular and behavioral evidence","volume":"35","author":"Trudell","year":"2014","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/bs.irn.2024.07.001_bib72","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1360-0443.1987.tb01494.x","article-title":"Uncontrollable events and alcohol drinking","volume":"82","author":"Volpicelli","year":"1987","journal-title":"British Journal of Addiction"},{"key":"10.1016\/bs.irn.2024.07.001_bib73","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"49","author":"Volpicelli","year":"1992","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/bs.irn.2024.07.001_bib74","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/0024-3205(86)90601-6","article-title":"Naltrexone blocks the post-shock increase of ethanol consumption","volume":"38","author":"Volpicelli","year":"1986","journal-title":"Life Sciences"},{"key":"10.1016\/bs.irn.2024.07.001_bib75","unstructured":"WHO (2023). Alcohol action plan 2022\u20132030. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"10.1016\/bs.irn.2024.07.001_bib76","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.2165\/00003495-199753060-00008","article-title":"Acamprosate. A review of its pharmacologyand clinical potential in the management of alcohol dependence afterdetoxification","volume":"53","author":"Wilde","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/bs.irn.2024.07.001_bib77","unstructured":"Winstock, A. R., Maier, L. J., Zhuparris, A., Davies, E., Puljevic, C., Kuypers, K. P. C., & Barratt, M. J. (2021). Global Drug Survey (GDS) 2021 Key findings report."},{"key":"10.1016\/bs.irn.2024.07.001_bib78","doi-asserted-by":"crossref","first-page":"eaax4043","DOI":"10.1126\/sciadv.aax4043","article-title":"Advances in the science and treatment of alcohol use disorder","volume":"5","author":"Witkiewitz","year":"2019","journal-title":"Science Advances"},{"key":"10.1016\/bs.irn.2024.07.001_bib79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0378-5173(02)00297-1","article-title":"Design of naltrexone-loaded hydrolyzable crosslinked nanoparticles","volume":"244","author":"Yin","year":"2002","journal-title":"International Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.001_bib80","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0014-2999(93)90682-8","article-title":"Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: Possible involvement of excitatory amino acid receptors","volume":"231","author":"Zeise","year":"1993","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.001_bib81","doi-asserted-by":"crossref","first-page":"32618","DOI":"10.1074\/jbc.M504942200","article-title":"Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G","volume":"280","author":"Zhang","year":"2005","journal-title":"Journal of Biological Chemistry"}],"container-title":["International Review of Neurobiology","Advances in Alcohol Use Disorder Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T14:06:17Z","timestamp":1753797977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774224000862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443296383"],"references-count":81,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2024.07.001","relation":{},"ISSN":["0074-7742"],"issn-type":[{"type":"print","value":"0074-7742"}],"subject":[],"published":{"date-parts":[[2024]]}}}